The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review.

Abstract

Proper antimicrobial prophylaxis is critical for reducing the risk of infection during interventional procedures. Brachytherapy, a highly effective radiation therapy for various malignancies, allows for precise radiation delivery; however, the use of foreign material as instrumentation for brachytherapy potentially increases the risk of infection. Understanding infectious complications and proper antimicrobial use in this case is essential for successful outcomes and patient safety. The aim of this review is to provide insights and summarize existing information on the infectious complications of brachytherapy in prostate, breast and gynaecological (cervical and endometrial) cancer, as well as on the potential benefit, if any, of administering antimicrobial prophylaxis. Infectious complication rates in prostate, breast and gynaecological cancer brachytherapy remain low with diverse prophylactic regimens, emphasizing the need to identify risk factors for tailored practices. The choice of the antimicrobial regimen, type of device and modality influences the probability of infectious complications. There is minimal overlap of existing brachytherapy guidelines with surgical prophylaxis guidelines. Infectious outcomes and antimicrobial resistance are underreported, and guidance for antimicrobial-resistant organisms is scarce. When indicated, prophylaxis for less than 24 h is efficient. More studies oriented towards antimicrobial prophylaxis on this specific population are needed.